{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:21:57Z","timestamp":1793467317599,"version":"4.5.0"},"reference-count":330,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jhepr.2026.101798","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:54:30Z","timestamp":1772006070000},"page":"101798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-1481","authenticated-orcid":false,"given":"Willem Pieter","family":"Brouwer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3999-9259","authenticated-orcid":false,"given":"Luisa","family":"Vonghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1854-1924","authenticated-orcid":false,"given":"Maja","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7771-9895","authenticated-orcid":false,"given":"Foteini","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Castera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8089-2907","authenticated-orcid":false,"given":"Cyrielle","family":"Caussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Cordie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5623-3300","authenticated-orcid":false,"given":"Ruth","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Fabrellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8305-7154","authenticated-orcid":false,"given":"Gema","family":"Fr\u00fchbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3334-4076","authenticated-orcid":false,"given":"Zouhir","family":"Gadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2594-1651","authenticated-orcid":false,"given":"Amalia","family":"Gastaldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Geerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9229-4127","authenticated-orcid":false,"given":"Laura","family":"Haigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-6970","authenticated-orcid":false,"given":"Kate","family":"Hallsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan","family":"Holleboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Lackner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-2299","authenticated-orcid":false,"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8095-7707","authenticated-orcid":false,"given":"Juan","family":"Mendive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6865-3791","authenticated-orcid":false,"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8200-6382","authenticated-orcid":false,"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy C.","family":"Spearman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horia","family":"Stefanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4657-7780","authenticated-orcid":false,"given":"Dina","family":"Tiniakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Tsochatsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1324-7497","authenticated-orcid":false,"given":"Shira","family":"Zelber-Sagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9598-4932","authenticated-orcid":false,"given":"Aleksander","family":"Krag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-4714","authenticated-orcid":false,"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101798_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101798_bib2","series-title":"MacSween\u2019s pathology of the liver","first-page":"330","article-title":"Fatty liver disease. Elsevier","author":"Tiniakos","year":"2023"},{"key":"10.1016\/j.jhepr.2026.101798_bib3","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101798_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/MCG.0000000000002202","article-title":"Prevalence of MASLD, Met-ALD, and ALD and associated fibrosis among US adults","author":"Paik","year":"2025","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"European association for the study of diabetes (EASD), European association for the study of obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib7","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American diabetes association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhepr.2026.101798_bib8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","article-title":"Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease","volume":"82","author":"Arab","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101798_bib12","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101798_bib13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2023.04.035","article-title":"A global research priority agenda to advance public health responses to fatty liver disease","volume":"79","author":"Lazarus","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib14","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/HEP.0000000000000545","article-title":"A global action agenda for turning the tide on fatty liver disease","volume":"79","author":"Lazarus","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib15","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"The Lancet"},{"key":"10.1016\/j.jhepr.2026.101798_bib16","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jhep.2025.06.020","article-title":"Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community","volume":"83","author":"Hansen","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41575-024-00959-4","article-title":"Food inequity and insecurity and MASLD: burden, challenges, and interventions","volume":"21","author":"Zelber-Sagi","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2023.11.021","article-title":"Preventing liver disease with policy measures to tackle alcohol consumption and obesity: the HEPAHEALTH II study","volume":"80","author":"Retat","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2468-1253(24)00220-6","article-title":"Best buy interventions to address the burden of steatotic liver disease","volume":"9","author":"Lazarus","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41575-024-00907-2","article-title":"Screening for liver fibrosis: lessons from colorectal and lung cancer screening","volume":"21","author":"Thiele","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib21","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S2468-1253(25)00097-4","article-title":"Screening for advanced steatotic liver disease","volume":"10","author":"Johansen","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib22","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101798_bib23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41575-021-00477-7","article-title":"Defining comprehensive models of care for NAFLD","volume":"18","author":"Lazarus","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib24","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/liv.15941","article-title":"Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: a qualitative exploration of challenges and barriers","volume":"44","author":"Tsochatzis","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101798_bib25","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib26","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hep.32642","article-title":"Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality","volume":"77","author":"van Kleef","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib27","article-title":"Differential prevalence and prognostic value of metabolic syndrome components among patients with MASLD","volume":"6","author":"Pustjens","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib28","article-title":"Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: a population-based study","volume":"13","author":"Juli\u00e1n","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jhepr.2026.101798_bib29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study","volume":"9","author":"Israelsen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib30","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.cgh.2020.11.038","article-title":"Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis","volume":"20","author":"Israelsen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib31","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"Marti-Aguado","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib33","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/hep.32635","article-title":"Fatty liver disease is not associated with increased mortality in the elderly: a prospective cohort study","volume":"77","author":"van Kleef","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib34","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/HEP.0000000000001440","article-title":"Call to action \u2013 pediatric MASLD requires immediate attention to curb health crisis","volume":"82","author":"Hartmann","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/j.gastro.2024.09.042","article-title":"Alcohol-associated liver disease: managing the dual Pathology of liver disease and of alcohol use disorder","volume":"168","author":"Arab","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101798_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fgstr.2022.1005729","article-title":"Sex-specific association between alcohol consumption and liver cirrhosis: an updated systematic review and meta-analysis","volume":"1","author":"Llamosas-Falc\u00f3n","year":"2022","journal-title":"Front Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib37","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.14309\/ajg.0000000000000340","article-title":"Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis","volume":"114","author":"Roerecke","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib38","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jhep.2025.05.013","article-title":"Cause-specific mortality in patients with steatotic liver disease in the United States","volume":"83","author":"Ochoa-Allemant","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1360-0443.2006.01310.x","article-title":"Rates and predictors of relapse after natural and treated remission from alcohol use disorders","volume":"101","author":"Moos","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.jhepr.2026.101798_bib40","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1186\/s12889-016-3542-7","article-title":"Temporal patterns of alcohol consumption and attempts to reduce alcohol intake in England","volume":"16","author":"de Vocht","year":"2016","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jhepr.2026.101798_bib41","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2468-1253(24)00427-8","article-title":"Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD","volume":"10","author":"Krag","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib42","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jhep.2025.07.019","article-title":"Phosphatidylethanol in steatotic liver disease","volume":"83","author":"Torp","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib43","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.cgh.2025.02.007","article-title":"Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments","volume":"23","author":"Israelsen","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib44","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/hepr.70067","article-title":"Young adults are at highest risk of liver fibrosis and mortality associated with steatotic liver disease with metabolic dysfunction and alcohol consumption","volume":"56","author":"Pustjens","year":"2026","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2026.101798_bib45","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2024.03.035","article-title":"Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases","volume":"81","author":"Thiele","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","article-title":"Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease","volume":"79","author":"Kjaergaard","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib47","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.gastro.2024.03.017","article-title":"Metabolic dysfunction\u2013associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction","volume":"167","author":"van Kleef","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101798_bib48","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000075","article-title":"The Steatosis-associated fibrosis estimator (SAFE) score: validation in the general US population","volume":"7","author":"van Kleef","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101798_bib49","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib50","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib51","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2021.08.017","article-title":"Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease \u2013 implications for the clinical utility of the EASL NIT guideline","volume":"76","author":"van Kleef","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.102512","article-title":"Diagnostic accuracy of the LiverRisk score to detect increased liver stiffness among a United States general population and subgroups","volume":"15","author":"van Kleef","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib53","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/hep.32545","article-title":"The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk NAFLD in primary care","volume":"77","author":"Sripongpun","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib54","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","article-title":"Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study","volume":"402","author":"Serra-Burriel","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.jhepr.2026.101798_bib55","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2468-1253(24)00274-7","article-title":"Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study","volume":"10","author":"Lindvig","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib56","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.cgh.2022.03.044","article-title":"Development and validation of a score for fibrotic nonalcoholic steatohepatitis","volume":"21","author":"Tavaglione","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib57","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib58","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/HEP.0000000000001356","article-title":"Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction","volume":"83","author":"van Kleef","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib59","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","article-title":"Serum markers detect the presence of liver fibrosis: a cohort study","volume":"127","author":"Rosenberg","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101798_bib60","series-title":"Non-alcoholic fatty liver disease: assessment and management. National Guideline Centre (UK)","year":"2016"},{"key":"10.1016\/j.jhepr.2026.101798_bib61","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jhepr.2026.101798_bib62","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/acer.12092","article-title":"AUDIT-C scores as a scaled marker of mean daily drinking, alcohol use disorder severity, and probability of alcohol dependence in a U.S. general population sample of drinkers","volume":"37","author":"Rubinsky","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.jhepr.2026.101798_bib63","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/acer.13364","article-title":"Two brief measures of alcohol use produce different results: AUDIT-C and quick drinking screen","volume":"41","author":"Letourneau","year":"2017","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.jhepr.2026.101798_bib64","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1176\/ajp.127.12.1653","article-title":"The Michigan alcoholism screening test: the quest for a new diagnostic instrument","volume":"127","author":"Selzer","year":"1971","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jhepr.2026.101798_bib65","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"key":"10.1016\/j.jhepr.2026.101798_bib66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1073191194001001004","article-title":"Comparison of timeline follow-back and averaging methods for quantifying alcohol consumption in treatment research","volume":"1","author":"Cervantes","year":"1994","journal-title":"Assessment"},{"key":"10.1016\/j.jhepr.2026.101798_bib67","article-title":"Detecting at-risk steatotic liver disease and liver fibrosis in the community","author":"Adams","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib68","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1186\/s12889-022-13724-6","article-title":"LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries","volume":"22","author":"Graupera","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jhepr.2026.101798_bib69","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.14309\/ajg.0000000000003268","article-title":"Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease","volume":"120","author":"Kim","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib70","article-title":"Palm-sized wireless transient elastography system with real-time B-mode ultrasound imaging guidance: toward point-of-care liver fibrosis assessment","volume":"14","author":"Huang","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jhepr.2026.101798_bib71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/acer.14512","article-title":"Diagnostic accuracy of biomarkers of alcohol use in patients with liver disease: a systematic review","volume":"45","author":"Arnts","year":"2021","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.jhepr.2026.101798_bib72","article-title":"Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake","volume":"7","author":"Hansen","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib73","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41746-024-01089-6","article-title":"A physiologically-based digital twin for alcohol consumption\u2014predicting real-life drinking responses and long-term plasma PEth","volume":"7","author":"Pod\u00e9us","year":"2024","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.jhepr.2026.101798_bib74","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.14309\/ajg.0000000000003178","article-title":"Using phosphatidylethanol as an adjunct to self-reported alcohol use improves identification of liver fibrosis risk","volume":"120","author":"Murnane","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib75","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2025.04.019","article-title":"Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes","volume":"83","author":"Vaz","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib76","doi-asserted-by":"crossref","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib77","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.cgh.2012.12.031","article-title":"External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study","volume":"11","author":"Koehler","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib78","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2012.11.021","article-title":"Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal","volume":"58","author":"Machado","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib79","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/jlts.2002.36740","article-title":"One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation","volume":"8","author":"Ryan","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2026.101798_bib80","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1478-3231.2012.02804.x","article-title":"Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD","volume":"32","author":"Ballestri","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101798_bib81","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ultrasmedbio.2024.03.014","article-title":"WFUMB guidelines\/guidance on liver multiparametric ultrasound. Part 2: guidance on liver fat quantification","volume":"50","author":"Ferraioli","year":"2024","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jhepr.2026.101798_bib82","doi-asserted-by":"crossref","first-page":"83","DOI":"10.14366\/usg.21076","article-title":"Accuracy of the ultrasound attenuation coefficient for the evaluation of hepatic steatosis: a systematic review and meta-analysis of prospective studies","volume":"41","author":"Jang","year":"2022","journal-title":"Ultrasonography"},{"key":"10.1016\/j.jhepr.2026.101798_bib83","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.ultrasmedbio.2024.08.008","article-title":"Ultraportable quantitative ultrasound for hepatic steatosis assessment","volume":"50","author":"H\u00e9riard-Dubreuil","year":"2024","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jhepr.2026.101798_bib84","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib85","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/oby.24033","article-title":"The grade of obesity affects the noninvasive diagnosis of advanced fibrosis in individuals with MASLD","volume":"32","author":"Chouik","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jhepr.2026.101798_bib86","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233094","article-title":"Reproducibility and repeatability of US shear-wave and transient elastography in nonalcoholic fatty liver disease","volume":"312","author":"Pierce","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2026.101798_bib87","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.dld.2022.10.009","article-title":"Non-invasive tools for compensated advanced chronic liver disease and portal hypertension after Baveno VII - an update","volume":"55","author":"Segna","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2026.101798_bib88","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.30163","article-title":"ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis","volume":"69","author":"Daniels","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib89","doi-asserted-by":"crossref","first-page":"235","DOI":"10.15403\/jgld-775","article-title":"Identification of patients with advanced fibrosis due to nonalcoholic fatty liver disease: considerations for best practice","volume":"29","author":"Augustin","year":"2020","journal-title":"J Gastrointest Liver Dis"},{"key":"10.1016\/j.jhepr.2026.101798_bib90","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.gastro.2024.12.039","article-title":"Liver health: an emerging concept","volume":"169","author":"Gin\u00e8s","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101798_bib91","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.14309\/ajg.0000000000002857","article-title":"ACG clinical guideline: focal liver lesions","volume":"119","author":"Frenette","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib92","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.cgh.2024.03.028","article-title":"Phenotypes of metabolic dysfunction\u2013associated steatotic liver disease\u2013associated hepatocellular carcinoma","volume":"22","author":"Rivera-Esteban","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib93","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21019","article-title":"Hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"Rodriguez","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhepr.2026.101798_bib94","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib95","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2022.10.010","article-title":"Time to focus on chronic liver diseases in the community: a review of primary care hepatology tools, pathways of care and reimbursement mechanisms","volume":"78","author":"Pryke","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib96","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/diseases12080180","article-title":"Practice recommendations for the management of MASLD in primary care: consensus results","volume":"12","author":"Lionis","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.jhepr.2026.101798_bib97","article-title":"Development and implementation of a continuing medical education program on non-alcoholic fatty liver disease for primary care practitioners in Europe","volume":"10","author":"Papadakis","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhepr.2026.101798_bib98","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S2468-1253(23)00270-4","article-title":"Implementation of a liver health check in people with type 2 diabetes","volume":"9","author":"Abeysekera","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib99","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S1665-2681(19)31174-3","article-title":"Prevalence in vulnerable population of liver fibrosis identified by transient elastography","volume":"14","author":"Ch\u00e1vez-Tapia","year":"2015","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib100","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.cgh.2019.01.026","article-title":"Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide","volume":"17","author":"Shah","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib101","doi-asserted-by":"crossref","DOI":"10.1093\/alcalc\/agae074","article-title":"Early detection of liver disease in patients with alcohol use disorder improves long-term abstinence","volume":"59","author":"Orgill","year":"2024","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.jhepr.2026.101798_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102069","article-title":"Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD): an open-label pragmatic feasibility randomised controlled trial","volume":"61","author":"Subhani","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhepr.2026.101798_bib103","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.cgh.2023.12.018","article-title":"Screening for fibrosis promotes lifestyle changes: a prospective cohort study in 4796 individuals","volume":"22","author":"Kjaergaard","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib104","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/liv.15895","article-title":"Proactive case finding of alcohol-related liver disease in high-risk populations: a systematic review","volume":"44","author":"Archer","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101798_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109981","article-title":"Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis","volume":"190","author":"Ciardullo","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jhepr.2026.101798_bib106","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2337\/dc24-2075","article-title":"Screening for metabolic dysfunction\u2013associated steatotic liver disease\u2013related advanced fibrosis in diabetology: a prospective multicenter study","volume":"48","author":"Caussy","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhepr.2026.101798_bib107","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s10620-015-3594-z","article-title":"High rate of hospital admissions among patients with cirrhosis seeking care in US emergency departments","volume":"60","author":"Ho","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2026.101798_bib108","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.1997","article-title":"Trends in the burden of chronic liver disease among hospitalized US adults","volume":"3","author":"Hirode","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhepr.2026.101798_bib109","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-66210-x","article-title":"Early screening for chronic liver disease: impact of a FIB-4 first integrated care pathway to identify patients with significant fibrosis","volume":"14","author":"Mignot","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib110","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/hep.32743","article-title":"Health disparities in chronic liver disease","volume":"77","author":"Kardashian","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib111","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL\u2013Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.jhepr.2026.101798_bib112","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib113","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2337\/dsi23-0009","article-title":"Practical lifestyle management of nonalcoholic fatty liver disease for busy clinicians","volume":"37","author":"Zelber-Sagi","year":"2024","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.jhepr.2026.101798_bib114","doi-asserted-by":"crossref","first-page":"75","DOI":"10.14309\/ajg.0000000000003215","article-title":"A pragmatic management approach for metabolic dysfunction-associated steatosis and steatohepatitis","volume":"120","author":"Shah","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib115","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/apt.17346","article-title":"A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis","volume":"57","author":"Younossi","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.101798_bib116","doi-asserted-by":"crossref","DOI":"10.14218\/JCTH.2024.00311","article-title":"Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (version 2024)","volume":"000","author":"Fan","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib117","first-page":"81","article-title":"The gordon Wilson lecture: COVID-19-lessons from the HIV pandemic","volume":"132","author":"Del","year":"2022","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.jhepr.2026.101798_bib118","author":"N."},{"key":"10.1016\/j.jhepr.2026.101798_bib119","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400062","article-title":"Hepatocellular cancer surveillance in patients with advanced chronic liver disease","volume":"3","author":"Gu","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2026.101798_bib120","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(23)01573-8","article-title":"Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial","volume":"402","author":"Kivuyo","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.jhepr.2026.101798_bib121","doi-asserted-by":"crossref","first-page":"e1375","DOI":"10.1016\/S2214-109X(19)30374-2","article-title":"Burden of non-communicable diseases in sub-Saharan Africa, 1990\u20132017: results from the global burden of disease study 2017","volume":"7","author":"Gouda","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jhepr.2026.101798_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102255","article-title":"The burden of non-communicable diseases among people living with HIV in Sub-Saharan Africa: a systematic review and meta-analysis","volume":"65","author":"Moyo-Chilufya","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhepr.2026.101798_bib123","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(06)68770-9","article-title":"Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data","volume":"367","author":"Lopez","year":"2006","journal-title":"The Lancet"},{"key":"10.1016\/j.jhepr.2026.101798_bib124","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-018-0306-9","article-title":"Acting on non-communicable diseases in low- and middle-income tropical countries","volume":"559","author":"Ezzati","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.101798_bib125","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.cgh.2025.06.014","article-title":"Risk factors of metabolic dysfunction-associated steatotic liver disease in a cohort of patients with chronic hepatitis B","volume":"24","author":"M.","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib126","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000689","article-title":"The global prevalence and impact of steatotic liver disease and viral infections: a systematic review and meta-analysis","volume":"9","author":"Li","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101798_bib127","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cgh.2025.04.024","article-title":"Association of metabolic comorbidities with fibrosis severity and fibrosis regression in patients with chronic hepatitis B","volume":"24","author":"van Velsen","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib128","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jhep.2024.10.032","article-title":"Metabolic dysfunction-associated steatohepatitis reduces interferon and macrophage liver gene signatures in patients with chronic hepatitis B","volume":"82","author":"Osmani","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cgh.2025.04.024","article-title":"Association of metabolic comorbidities with fibrosis severity and fibrosis regression in patients with chronic hepatitis B","volume":"24","author":"van Velsen","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib130","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/hep.30857","article-title":"Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B","volume":"71","author":"Choi","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101798_bib131","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/apt.70360","article-title":"Prediction of hepatocellular carcinoma and other liver-related events in chronic hepatitis B patients with metabolic dysfunction or metabolic dysfunction-associated steatotic liver disease","volume":"63","author":"Patmore","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.101798_bib132","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2025.12.026","article-title":"Is liver steatosis a disease or the emperor\u2019s new clothes?","volume":"84","author":"A.","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib133","article-title":"Non-alcoholic fatty liver disease: a patient guideline","volume":"3","author":"Francque","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib134","first-page":"4390","article-title":"Integrating population and individual services to reduce health inequalities at community level","volume":"15","author":"Vesna Petric","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.jhepr.2026.101798_bib135","unstructured":"https:\/\/circeja.nfz.gov.pl\/bp6-slovenia. BP6 | Health Promotion Centres (HPCs) \u2013 Slovenia n.d."},{"key":"10.1016\/j.jhepr.2026.101798_bib136","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111846","article-title":"Diabetes as a risk factor for MASH progression","volume":"217","author":"Gancheva","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jhepr.2026.101798_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111648","article-title":"Epidemiology of NAFLD - focus on diabetes","volume":"210","author":"Younossi","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jhepr.2026.101798_bib139","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib140","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2337\/dc22-2048","article-title":"High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold","volume":"46","author":"Castera","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhepr.2026.101798_bib141","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"R.","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101798_bib142","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1136\/gutjnl-2024-332481","article-title":"Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease","volume":"73","author":"Mao","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101798_bib143","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/dom.14650","article-title":"Combination therapy with pioglitazone\/exenatide\/metformin reduces the prevalence of hepatic fibrosis and steatosis: the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)","volume":"24","author":"Lavynenko","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhepr.2026.101798_bib144","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"A.J.","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101798_bib145","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101798_bib146","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.101798_bib147","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib148","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.cgh.2022.10.022","article-title":"Cardiovascular outcomes in patients with biopsy-proven alcohol-related liver disease","volume":"21","author":"Hagstr\u00f6m","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib149","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials","volume":"385","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.jhepr.2026.101798_bib150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","article-title":"Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Mellemkj\u00e6r","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhepr.2026.101798_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101816","article-title":"Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis","volume":"46","author":"Fatima","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib152","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","article-title":"Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes","volume":"136","author":"El\u2013Serag","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101798_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhepr.2026.101798_bib154","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.101798_bib155","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.cgh.2019.04.061","article-title":"Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease","volume":"17","author":"Simon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib156","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1001\/jama.2024.1215","article-title":"Aspirin for metabolic dysfunction\u2013associated steatotic liver disease without cirrhosis","volume":"331","author":"Simon","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jhepr.2026.101798_bib157","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/14737159.2023.2242779","article-title":"Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease","volume":"23","author":"Armandi","year":"2023","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.jhepr.2026.101798_bib158","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101798_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108811","article-title":"Insights into the results of Resmetirom trials: can a thyroid hormone receptor agonist be the holy grail of MASH therapy?","volume":"268","author":"Arvanitakis","year":"2025","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.101798_bib160","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis","volume":"22","author":"Noureddin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib161","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib162","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S2468-1253(23)00100-0","article-title":"Diagnosis of fatty liver in children should occur in parallel to investigation for other causes of liver disease","volume":"8","author":"Mann","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib163","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jhep.2018.02.006","article-title":"Paediatric fatty liver disease (PeFLD): all is not NAFLD \u2013 pathophysiological insights and approach to management","volume":"68","author":"Hegarty","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib164","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/jpn3.12156","article-title":"Paediatric steatotic liver disease has unique characteristics: a multisociety statement endorsing the new nomenclature","volume":"78","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhepr.2026.101798_bib165","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.cgh.2021.11.039","article-title":"Intensive lifestyle management improves steatosis and fibrosis in pediatric nonalcoholic fatty liver disease","volume":"20","author":"Lefere","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib166","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3945\/ajcn.111.018366","article-title":"Consumption of added sugars is decreasing in the United States","volume":"94","author":"Welsh","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jhepr.2026.101798_bib167","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.12759","article-title":"The relationship between excessive dietary fructose consumption and paediatric fatty liver disease","volume":"16","author":"DiStefano","year":"2021","journal-title":"Pediatr Obes"},{"key":"10.1016\/j.jhepr.2026.101798_bib168","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/cld.1093","article-title":"Transition of care model for pediatric patients with nonalcoholic fatty liver disease","volume":"18","author":"Mitrani","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.jhepr.2026.101798_bib169","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263931","article-title":"Lifestyle changes in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"17","author":"Fern\u00e1ndez","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2026.101798_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154455","article-title":"The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"115","author":"Koutoukidis","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.jhepr.2026.101798_bib171","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ije\/dyab174","article-title":"Ultra-processed food consumption and the risk of non-alcoholic fatty liver disease in the Tianjin chronic low-grade systemic inflammation and health cohort study","volume":"51","author":"Zhang","year":"2022","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jhepr.2026.101798_bib172","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1161\/CIR.0000000000001031","article-title":"2021 dietary guidance to improve cardiovascular health: a scientific statement from the American heart association","volume":"144","author":"Lichtenstein","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jhepr.2026.101798_bib173","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0041-1723751","article-title":"Effects of mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials","volume":"41","author":"Kawaguchi","year":"2021","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2026.101798_bib174","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clnu.2021.12.014","article-title":"Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: evidence from mediation analysis","volume":"41","author":"Kim","year":"2022","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jhepr.2026.101798_bib175","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/ajcn\/nqaa380","article-title":"Soft drink consumption and risk of nonalcoholic fatty liver disease: results from the Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIH) cohort study","volume":"113","author":"Zhang","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jhepr.2026.101798_bib176","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Z.M.","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0007114520000914","article-title":"Food groups and the likelihood of non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"124","author":"He","year":"2020","journal-title":"Br J Nutr"},{"key":"10.1016\/j.jhepr.2026.101798_bib178","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12902-022-01015-5","article-title":"Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials","volume":"22","author":"Peng","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.jhepr.2026.101798_bib179","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1017\/S0007114522003956","article-title":"Association between ultra-processed foods consumption and risk of non-alcoholic fatty liver disease: a population-based analysis of NHANES 2011\u20132018","volume":"130","author":"Liu","year":"2023","journal-title":"Br J Nutr"},{"key":"10.1016\/j.jhepr.2026.101798_bib180","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jhep.2018.01.015","article-title":"High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance","volume":"68","author":"Zelber-Sagi","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib181","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41575-021-00472-y","article-title":"Dietary carbohydrates and fats in nonalcoholic fatty liver disease","volume":"18","author":"Yki-J\u00e4rvinen","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib182","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ajcn\/nqaa332","article-title":"Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial","volume":"113","author":"Simons","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jhepr.2026.101798_bib183","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jhep.2021.02.027","article-title":"Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial","volume":"75","author":"Geidl-Flueck","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib184","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.cgh.2021.11.001","article-title":"Sugar-sweetened beverage, diet soda, and nonalcoholic fatty liver disease over 6 Years: the framingham heart study","volume":"20","author":"Park","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cmet.2022.12.001","article-title":"Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: a randomized controlled trial","volume":"35","author":"Ezpeleta","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2026.101798_bib186","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.3513","article-title":"Effects of time-restricted eating on nonalcoholic fatty liver disease","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhepr.2026.101798_bib187","article-title":"Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet \u2013 a randomised controlled trial","volume":"3","author":"Holmer","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib188","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/hep.31251","article-title":"Plant-based and animal-based low-carbohydrate diets and risk of hepatocellular carcinoma among US men and women","volume":"73","author":"Liu","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib189","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/hep.30362","article-title":"Dietary patterns and risk of hepatocellular carcinoma among U.S. Men and women","volume":"70","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib190","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hep4.1313","article-title":"High-quality diets are associated with reduced risk of hepatocellular carcinoma and chronic liver disease: the multiethnic cohort","volume":"3","author":"Bogumil","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101798_bib191","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jama.2023.12618","article-title":"Sugar-sweetened and artificially sweetened beverages and risk of liver cancer and chronic liver disease mortality","volume":"330","author":"Zhao","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jhepr.2026.101798_bib192","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/ije\/dyz146","article-title":"Meat intake and risk of hepatocellular carcinoma in two large US prospective cohorts of women and men","volume":"48","author":"Ma","year":"2019","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jhepr.2026.101798_bib193","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.01.016","article-title":"Cigarette smoking and liver diseases","volume":"77","author":"Marti-Aguado","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib194","article-title":"Physical activity is associated with reduced risk of liver disease in the prospective UK Biobank cohort","volume":"3","author":"Schneider","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib195","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41416-020-0741-x","article-title":"Combined lifestyle factors, incident cancer, and cancer mortality: a systematic review and meta-analysis of prospective cohort studies","volume":"122","author":"Zhang","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2026.101798_bib196","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1158\/1055-9965.EPI-20-1201","article-title":"Composite score of healthy lifestyle factors and risk of hepatocellular carcinoma: findings from a prospective cohort study","volume":"30","author":"Luu","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jhepr.2026.101798_bib197","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000499","article-title":"Digital therapeutics lead to clinically significant body weight loss in patients with metabolic dysfunction\u2013associated steatotic liver disease: a systematic review and meta-analysis","volume":"8","author":"Albhaisi","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101798_bib198","article-title":"Effectiveness and active ingredients of digital behaviour change interventions for MASLD: a systematic review and meta-analysis","volume":"7","author":"Smith","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib199","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/flgastro-2014-100432","article-title":"Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls","volume":"6","author":"Hallsworth","year":"2015","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib200","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.amjms.2021.09.007","article-title":"Physical activity, inactivity and sleep in patients with significant non-alcoholic fatty liver disease","volume":"363","author":"Scragg","year":"2022","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jhepr.2026.101798_bib201","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1249\/MSS.0000000000001901","article-title":"Physical activity and sedentary time: association with metabolic health and liver fat","volume":"51","author":"Bowden Davies","year":"2019","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.jhepr.2026.101798_bib202","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/hep.22137","article-title":"Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease","volume":"47","author":"Krasnoff","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib203","series-title":"At least five a week. Evidence on the impact of physical activity and its relationship to health. A report from the Chief medical officer","year":"2004"},{"key":"10.1016\/j.jhepr.2026.101798_bib204","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.14309\/ajg.0000000000002098","article-title":"Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body weight loss in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"118","author":"Stine","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib205","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s40279-023-01918-w","article-title":"Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: a position statement from exercise and sport science Australia","volume":"53","author":"Keating","year":"2023","journal-title":"Sports Med"},{"key":"10.1016\/j.jhepr.2026.101798_bib206","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000108","article-title":"American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease","volume":"7","author":"Stine","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101798_bib207","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11894-016-0485-1","article-title":"Targeting lifestyle behavior change in adults with NAFLD during a 20-min consultation: summary of the dietary and exercise literature","volume":"18","author":"Hallsworth","year":"2016","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib208","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhepr.2019.10.008","article-title":"Lifestyle modification in NAFLD\/NASH: facts and figures","volume":"1","author":"Hallsworth","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib209","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-0040-1716564","article-title":"Wearables, physical activity, and exercise testing in liver disease","volume":"41","author":"Dunn","year":"2021","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2026.101798_bib210","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000413","article-title":"Pragmatic strategies to address health disparities along the continuum of care in chronic liver disease","volume":"8","author":"Brahmania","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101798_bib211","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/hep4.1681","article-title":"The patient\u2019s perspective in cirrhosis: unmet supportive care needs differ by disease severity, etiology, and age","volume":"5","author":"Valery","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101798_bib212","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.31117","article-title":"Nursing care of patients with cirrhosis: the LiverHope nursing project","volume":"71","author":"Fabrellas","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib213","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhep.2023.01.029","article-title":"Nursing care for patients with cirrhosis","volume":"79","author":"Fabrellas","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib214","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.cgh.2019.07.043","article-title":"Integrated model for patient-centered advanced liver disease care","volume":"18","author":"Naik","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278545","article-title":"Nurse-assisted and multidisciplinary outpatient follow-up among patients with decompensated liver cirrhosis: a systematic review","volume":"18","author":"O\u2019Connell","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2026.101798_bib216","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1111\/jocn.15416","article-title":"Self-management programmes for cirrhosis: a systematic review","volume":"29","author":"Boudreault","year":"2020","journal-title":"J Clin Nurs"},{"key":"10.1016\/j.jhepr.2026.101798_bib217","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S2589-7500(24)00174-2","article-title":"The new digital era in decompensated cirrhosis","volume":"7","author":"Gananandan","year":"2025","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.jhepr.2026.101798_bib218","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000498","article-title":"Design, implementation, and impact of a cirrhosis-specific remote patient monitoring program","volume":"8","author":"Penrice","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101798_bib219","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12912-024-01934-9","article-title":"Patient perceived quality of cirrhosis care\u2013 adjunctive nurse-based care versus standard medical care: a pragmatic multicentre randomised controlled study","volume":"23","author":"Hjorth","year":"2024","journal-title":"BMC Nurs"},{"key":"10.1016\/j.jhepr.2026.101798_bib220","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/SGA.0000000000000706","article-title":"A nurse-led outpatient clinic for patients with decompensated liver cirrhosis","volume":"46","author":"Hamberg","year":"2023","journal-title":"Gastroenterol Nurs"},{"key":"10.1016\/j.jhepr.2026.101798_bib221","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/hep.30695","article-title":"The quality and outcomes of care provided to patients with cirrhosis by advanced practice providers","volume":"71","author":"Tapper","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib222","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3138\/canlivj-2020-0017","article-title":"Impact of specialized multidisciplinary care on cirrhosis outcomes and acute care utilization","volume":"4","author":"Carbonneau","year":"2021","journal-title":"Can Liver J"},{"key":"10.1016\/j.jhepr.2026.101798_bib223","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/j.cgh.2019.12.035","article-title":"Coordination of care is associated with survival and health care utilization in a population-based study of patients with cirrhosis","volume":"18","author":"Cohen-Mekelburg","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib224","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s10620-023-08212-9","article-title":"Low health literacy, lack of knowledge, and self-control hinder healthy lifestyles in diverse patients with steatotic liver disease","volume":"69","author":"Figueroa","year":"2024","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2026.101798_bib225","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000145","article-title":"Management of alcohol use disorder in patients with chronic liver disease","volume":"7","author":"Mellinger","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101798_bib226","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jhep.2018.08.028","article-title":"Supportive and palliative care in people with cirrhosis: international systematic review of the perspective of patients, family members and health professionals","volume":"69","author":"Low","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib227","unstructured":"https:\/\/liverpatientsinternational.org\/steatotic-liver-disease n.d."},{"key":"10.1016\/j.jhepr.2026.101798_bib228","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib229","article-title":"Limitations of non-invasive tests for assessment of liver fibrosis","volume":"2","author":"Patel","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib230","article-title":"Validation of NIAAAm-CRP criteria to predict alcohol-associated steatohepatitis on liver histology","volume":"6","author":"Stauber","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib231","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2021.05.029","article-title":"Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease","volume":"75","author":"Lackner","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib232","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL clinical practice guidelines: management of alcohol-related liver disease","volume":"69","author":"Thursz","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib233","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib234","doi-asserted-by":"crossref","first-page":"723","DOI":"10.14309\/ajg.0000000000000994","article-title":"Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease","volume":"116","author":"Pons","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib235","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","article-title":"An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography","volume":"79","author":"Liang","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib236","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"M\u00f3zes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib237","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.cgh.2023.08.004","article-title":"Point-of-Care noninvasive prediction of liver-related events in patients with nonalcoholic fatty liver disease","volume":"22","author":"Pons","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib238","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1053\/j.gastro.2023.06.030","article-title":"Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease","volume":"165","author":"Semmler","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101798_bib239","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib240","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.21984","article-title":"Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers","volume":"47","author":"Guha","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib241","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.30846","article-title":"Defining the minimum acceptable diagnostic accuracy of noninvasive fibrosis testing in cirrhosis: a decision analytic modeling study","volume":"71","author":"Majumdar","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib242","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jhep.2024.05.033","article-title":"Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD","volume":"81","author":"R.","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib243","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrgastro.2009.149","article-title":"The clinical use of HVPG measurements in chronic liver disease","volume":"6","author":"Bosch","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib244","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib245","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2468-1253(23)00150-4","article-title":"Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis","volume":"8","author":"Dajti","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib246","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ultrasmedbio.2024.03.013","article-title":"WFUMB guideline\/guidance on liver multiparametric ultrasound: Part 1. Update to 2018 guidelines on liver ultrasound elastography","volume":"50","author":"Ferraioli","year":"2024","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jhepr.2026.101798_bib247","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/HEP.0000000000000844","article-title":"AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib248","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S2468-1253(24)00234-6","article-title":"Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study","volume":"9","author":"Jachs","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib249","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.cgh.2021.10.023","article-title":"Decompensation in advanced nonalcoholic fatty liver disease may occur at lower hepatic venous pressure gradient levels than in patients with viral disease","volume":"20","author":"Bassegoda","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib250","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib251","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2021.11.025","article-title":"HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease","volume":"76","author":"Semmler","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib252","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.cgh.2020.06.045","article-title":"Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease","volume":"19","author":"Petta","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib253","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jhep.2019.12.001","article-title":"Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound","volume":"72","author":"Park","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib254","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000501082","article-title":"B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial","volume":"8","author":"Kudo","year":"2019","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101798_bib255","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/hep.29848","article-title":"Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy","volume":"68","author":"Zamora-Valdes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib256","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.28992","article-title":"Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study","volume":"65","author":"Berzigotti","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib257","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph21060708","article-title":"The long-term effect of weight loss on the prevention of progression to cirrhosis among patients with obesity and MASH-related F3 liver fibrosis","volume":"21","author":"Niu","year":"2024","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jhepr.2026.101798_bib258","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2024.112571","article-title":"Sarcopenia in cirrhosis: from pathophysiology to interventional therapy","volume":"196","author":"Chen","year":"2024","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.jhepr.2026.101798_bib259","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.cgh.2022.11.033","article-title":"Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis","volume":"21","author":"Hofer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib260","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/apt.17888","article-title":"Meta-analysis: prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis","volume":"59","author":"Lim","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.101798_bib261","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.32049","article-title":"Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American association for the study of liver diseases","volume":"74","author":"Lai","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib262","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/j.clnu.2020.09.001","article-title":"ESPEN practical guideline: clinical nutrition in liver disease","volume":"39","author":"Bischoff","year":"2020","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jhepr.2026.101798_bib263","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jcsm.12039","article-title":"Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis","volume":"7","author":"Montano-Loza","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jhepr.2026.101798_bib264","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","article-title":"EASL Clinical Practice Guidelines on nutrition in chronic liver disease","volume":"70","author":"Merli","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib265","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/jgh.16035","article-title":"Home-based intensive nutrition therapy improves frailty and sarcopenia in patients with decompensated cirrhosis: a randomized clinical trial","volume":"38","author":"Meena","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib266","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1111\/jgh.16266","article-title":"Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: a double-blind randomized controlled trial","volume":"38","author":"Sharma","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib267","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.nut.2013.05.016","article-title":"Nutrition therapy using a multidisciplinary team improves survival rates in patients with liver cirrhosis","volume":"29","author":"Iwasa","year":"2013","journal-title":"Nutrition"},{"key":"10.1016\/j.jhepr.2026.101798_bib268","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1440-1746.2011.06951.x","article-title":"Late evening snack: exploiting a period of anabolic opportunity in cirrhosis","volume":"27","author":"Tsien","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib269","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/hep.22367","article-title":"Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis","volume":"48","author":"Plank","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib270","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.clnu.2023.03.021","article-title":"Practical guideline on obesity care in patients with gastrointestinal and liver diseases \u2013 joint ESPEN\/UEG guideline","volume":"42","author":"Bischoff","year":"2023","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jhepr.2026.101798_bib271","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/hep.24418","article-title":"Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis","volume":"54","author":"Berzigotti","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib272","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/apt.15491","article-title":"Review article: impact of exercise on physical frailty in patients with chronic liver disease","volume":"50","author":"Williams","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.101798_bib273","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.14309\/ajg.0000000000001883","article-title":"Outcomes of exercise interventions in patients with advanced liver disease: a systematic review of randomized clinical trials","volume":"117","author":"Jamali","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib274","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11894-016-0516-y","article-title":"Sarcopenia in patients with chronic liver disease: can it Be altered by diet and exercise?","volume":"18","author":"Kappus","year":"2016","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib275","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2016.38","article-title":"Changes in hepatic venous pressure gradient induced by physical exercise in cirrhosis: results of a pilot randomized open clinical trial","volume":"7","author":"Mac\u00edas-Rodr\u00edguez","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101798_bib276","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/lt.25442","article-title":"Home-based exercise in patients awaiting liver transplantation: a feasibility study","volume":"25","author":"Williams","year":"2019","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhepr.2026.101798_bib277","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.trre.2016.07.004","article-title":"Safety, adherence and efficacy of exercise training in solid-organ transplant candidates: a systematic review","volume":"30","author":"Wallen","year":"2016","journal-title":"Transpl Rev"},{"key":"10.1016\/j.jhepr.2026.101798_bib278","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/lt.24958","article-title":"Exercise and physical activity for patients with end-stage liver disease: improving functional status and sarcopenia while on the transplant waiting list","volume":"24","author":"Duarte-Rojo","year":"2018","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhepr.2026.101798_bib279","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2018.06.017","article-title":"Exercise in cirrhosis: translating evidence and experience to practice","volume":"69","author":"Tandon","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib280","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/hep.28132","article-title":"Physical activity and liver diseases","volume":"63","author":"Berzigotti","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib281","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.cgh.2011.07.007","article-title":"Increased perioperative mortality following bariatric surgery among patients with cirrhosis","volume":"9","author":"Mosko","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib282","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101798_bib283","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.32358","article-title":"Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery","volume":"76","author":"Pais","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib284","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib285","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jhep.2020.10.003","article-title":"Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis","volume":"74","author":"Ferrusqu\u00eda-Acosta","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib286","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/LVT.0000000000000372","article-title":"Bariatric surgery post-liver transplantation: a Belgian nationwide study","volume":"30","author":"Onghena","year":"2024","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2026.101798_bib287","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/ueg2.12642","article-title":"Prior metabolic and bariatric surgery is an independent determinant of severity of decompensation in alcohol-associated liver disease","volume":"12","author":"Onghena","year":"2024","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhepr.2026.101798_bib288","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.sla.0000171327.29262.e0","article-title":"Model for end-stage liver disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis","volume":"242","author":"Northup","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhepr.2026.101798_bib289","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cgh.2018.09.043","article-title":"AGA clinical practice update on surgical risk assessment and perioperative management in cirrhosis: expert review","volume":"17","author":"Northup","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib290","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2011.06.027","article-title":"Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors","volume":"56","author":"Llop","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib291","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.gassur.2005.09.008","article-title":"Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of end-stage liver disease (MELD) score predicts perioperative mortality","volume":"9","author":"Teh","year":"2005","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.jhepr.2026.101798_bib292","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ejcts.2010.02.042","article-title":"Risk prediction and outcomes in patients with liver cirrhosis undergoing open-heart surgery","volume":"38","author":"Thielmann","year":"2010","journal-title":"Eur J Cardio-Thoracic Surg"},{"key":"10.1016\/j.jhepr.2026.101798_bib293","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1542-3565(04)00296-4","article-title":"Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores","volume":"2","author":"Suman","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib294","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1051\/ject\/201749283","article-title":"TEG-directed transfusion in complex cardiac surgery: impact on blood product usage","volume":"49","author":"Fleming","year":"2017","journal-title":"J Extra Corpor Technol"},{"key":"10.1016\/j.jhepr.2026.101798_bib295","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","article-title":"Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study","volume":"71","author":"Haldar","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib296","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2023.03.014","article-title":"A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials","volume":"79","author":"Pais","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib297","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/HEP.0000000000000735","article-title":"Metabolic dysfunction-associated steatotic liver disease and the heart","volume":"82","author":"Driessen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib298","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4254\/wjh.v10.i11.877","article-title":"Cardiac stress testing and coronary artery disease in liver transplantation candidates: meta-analysis","volume":"10","author":"Soldera","year":"2018","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib299","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/TP.0000000000002433","article-title":"International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation","volume":"103","author":"Tsochatzis","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.jhepr.2026.101798_bib300","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/hep.29848","article-title":"Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy","volume":"68","author":"Zamora-Valdes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib301","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/lt.25637","article-title":"Delayed sleeve gastrectomy following liver transplantation: a 5-year experience","volume":"25","author":"Morris","year":"2019","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhepr.2026.101798_bib302","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2468-1253(19)30181-5","article-title":"Management of metabolic syndrome and cardiovascular risk after liver transplantation","volume":"4","author":"Fatourou","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib303","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/apt.12324","article-title":"Review article: prescribing medications in patients with cirrhosis \u2013 a practical guide","volume":"37","author":"Lewis","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.101798_bib304","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40264-017-0635-x","article-title":"Evidence-based recommendations to improve the safe use of drugs in patients with liver cirrhosis","volume":"41","author":"Weersink","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.jhepr.2026.101798_bib305","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012991","article-title":"Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion","volume":"6","author":"Weersink","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhepr.2026.101798_bib306","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1097\/HEP.0000000000000263","article-title":"Diabetes and cirrhosis: current concepts on diagnosis and management","volume":"77","author":"Castera","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib307","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101272","article-title":"Management of diabetes mellitus in patients with cirrhosis: an overview and joint statement","volume":"47","author":"Boursier","year":"2021","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jhepr.2026.101798_bib308","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102935","article-title":"Management of type 2 diabetes in patients with compensated liver cirrhosis: short of evidence, plenty of potential","volume":"18","author":"Arvanitakis","year":"2024","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"10.1016\/j.jhepr.2026.101798_bib309","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cgh.2020.04.083","article-title":"Type 2 diabetes and metformin use associate with outcomes of patients with nonalcoholic steatohepatitis\u2013related, child\u2013pugh A cirrhosis","volume":"19","author":"Vilar-Gomez","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib310","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/apt.17925","article-title":"Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes","volume":"59","author":"Elsaid","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.101798_bib311","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib312","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","article-title":"Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease","volume":"184","author":"Jang","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhepr.2026.101798_bib313","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.amjcard.2005.12.014","article-title":"An assessment of statin safety by hepatologists","volume":"97","author":"Cohen","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jhepr.2026.101798_bib314","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib315","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.2337\/dc25-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhepr.2026.101798_bib316","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","article-title":"Breakthroughs in therapies for NASH and remaining challenges","volume":"76","author":"Ratziu","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib317","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis","volume":"82","author":"Souza","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib318","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186425","article-title":"Therapeutic horizons in metabolic dysfunction\u2013associated steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2026.101798_bib319","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.cgh.2017.12.048","article-title":"High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study","volume":"16","author":"Caballer\u00eda","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib320","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jhep.2022.04.009","article-title":"Structured early detection of asymptomatic liver cirrhosis: results of the population-based liver screening program SEAL","volume":"77","author":"Labenz","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib321","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S2468-1253(16)30205-9","article-title":"Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review","volume":"2","author":"Harris","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib322","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ueg2.12511","article-title":"Obesity and harmful alcohol consumption are predictors for advanced liver disease in the disease management program for type 2 diabetes","volume":"12","author":"Michel","year":"2024","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhepr.2026.101798_bib323","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1136\/gutjnl-2024-332917","article-title":"Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA","volume":"73","author":"Yang","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101798_bib324","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/liv.15730","article-title":"A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies","volume":"44","author":"Forlano","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101798_bib325","article-title":"Liver fibrosis screening increases alcohol abstinence","volume":"6","author":"Avitabile","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101798_bib326","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/HEP.0000000000000604","article-title":"National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature","volume":"79","author":"Lee","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib327","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1053\/j.gastro.2023.05.053","article-title":"Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China","volume":"165","author":"Man","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101798_bib328","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.27981","article-title":"Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study","volume":"63","author":"Koehler","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101798_bib329","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.cgh.2024.08.020","article-title":"Global prevalence of advanced liver fibrosis and cirrhosis in the general population: a systematic review and meta-analysis","volume":"23","author":"Zamani","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101798_bib330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266069","article-title":"Liver stiffness as surrogate parameter in emergency assessment for inpatient health care utilization","volume":"17","author":"Kaddu-Mulindwa","year":"2022","journal-title":"PLoS One"}],"updated-by":[{"DOI":"10.1016\/j.jhepr.2026.102061","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000}}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926000698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926000698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:20:04Z","timestamp":1790112004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":330,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2589555926000698"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101798","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101798"}}